Crossref
journal-article
Elsevier BV
Clinical Immunology (78)
References
101
Referenced
143
10.1182/blood.V66.4.848.848
/ Blood / The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed–Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells by Stein (1985){'key': '10.1006/clim.1998.4636_RF2', 'series-title': 'Neoplastic Hematopathology', 'author': 'Stein', 'year': '1992'}
/ Neoplastic Hematopathology by Stein (1992)10.1016/0092-8674(94)90372-7
/ Cell / The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death by Smith (1994)10.1182/blood.V85.12.3378.bloodjournal85123378
/ Blood / Tumor necrosis factor ligand superfamily: Involvement in the pathology of malignant lymphomas by Gruss (1995)10.1016/0092-8674(92)90180-K
/ Cell / Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease by Durkop (1992)10.4049/jimmunol.139.6.2081
/ J. Immunol. / Biochemical characterization and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines by Froese (1987)10.1515/bchm3.1989.370.1.409
/ Biol. Chem. Hoppe Seyler / The Hodgkin-associated Ki-1 antigen exists in an intracellular and a membrane-bound form by Hansen (1989)10.1074/jbc.271.22.12852
/ J. Biol. Chem. / CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins by Gedrich (1996)10.1073/pnas.93.18.9699
/ Proc. Natl. Acad. Sci. USA / CD30/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity by Lee (1996)10.1074/jbc.272.4.2042
/ J. Biol. Chem. / Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation by Aizawa (1997)10.1093/intimm/10.2.203
/ Int. Immunol. / A novel domain in the CD30 cytoplasmic tail mediates NFkappaB activation by Horie (1998)10.1002/ijc.2910630524
/ Int. J. Cancer / A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines by Hansen (1995)10.1002/ijc.2910600419
/ Int. J. Cancer / Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4) by Horn-Lohrens (1995){'key': '10.1006/clim.1998.4636_RF14', 'first-page': '3353', 'article-title': 'Expression of cytokine genes, cytokine receptor genes, and transcription factors in cultured Hodgkin and Reed-Sternberg cells', 'volume': '52', 'author': 'Gruss', 'year': '1992', 'journal-title': 'Cancer Res.'}
/ Cancer Res. / Expression of cytokine genes, cytokine receptor genes, and transcription factors in cultured Hodgkin and Reed-Sternberg cells by Gruss (1992)10.1182/blood.V83.8.2045.2045
/ Blood / Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines by Gruss (1994)10.1002/eji.1830251024
/ Eur. J. Immunol. / CD30 ligation induces nuclear factor-kappa B activation in human T cell lines by McDonald (1995)10.1128/MCB.17.3.1535
/ Mol. Cell. Biol. / Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2 by Duckett (1997)10.4049/jimmunol.151.11.5896
/ J. Immunol. / Functional effects of CD30 on a large granular lymphoma cell line, YT by Bowen (1993)10.1016/1074-7613(95)90003-9
/ Immunity / Cross-linking of CD30 induces HIV expression in chronically infected T cells by Biswas (1995)10.1182/blood.V88.7.2422.bloodjournal8872422
/ Blood / A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages by Horie (1996)10.1016/0092-8674(93)90132-A
/ Cell / Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: Implications for TNF receptor activation by Banner (1993)10.1002/jlb.63.6.752
/ J. Leukoc. Biol. / Construction and expression of a soluble form of human CD30 ligand with functional activity by Powell (1998)10.4049/jimmunol.156.2.442
/ J. Immunol. / Structure and expression of murine CD30 and its role in cytokine production by Bowen (1996)- Chiarle, R. Podda, A. Prolla, G. Podack, E. R. Thorbecke, G. J. Inghirami, G. CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a caspase and Bcl-2 sensitive pathway, Submitted.
10.4049/jimmunol.160.5.2180
/ J. Immunol. / Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines by Gilfillan (1998)10.1016/S0378-1119(96)00542-2
/ Gene / Cloning and characterization of a cDNA for rat CD30 homolog and chromosomal assignment of the genomic gene by Aizawa (1996)10.1136/jcp.39.9.993
/ J. Clin. Pathol. / High proliferative activity of Reed Sternberg associated antigen Ki-1 positive cells in normal lymphoid tissue by Gerdes (1986)10.1182/blood.V90.6.2445
/ Blood / BCL-6 protein expression in human peripheral T-cell neoplasms is restricted to CD30+ anaplastic large-cell lymphomas by Carbone (1997)10.1182/blood.V91.9.3323
/ Blood / High CD30 ligand expression by epithelial cells and Hassal's corpuscles in the medulla of human thymus by Romagnani (1998)10.4049/jimmunol.157.8.3229
/ J. Immunol. / CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes of normal donors by Agrawal (1996)10.1111/j.1365-2141.1993.tb03166.x
/ Br. J. Haematol. / Cultured human NK cells express the Ki-1/CD30 antigen by Cambiaggi (1993)10.1111/j.1365-2559.1993.tb00476.x
/ Histopathology / Expression of CD30 and nerve growth factor-receptor in neoplastic and reactive vascular lesions: An immunohistochemical study by Rudolph (1993){'key': '10.1006/clim.1998.4636_RF33', 'first-page': '276', 'article-title': 'High expression of the CD30 molecule in human decidual cells', 'volume': '145', 'author': 'Ito', 'year': '1994', 'journal-title': 'Am. J. Pathol.'}
/ Am. J. Pathol. / High expression of the CD30 molecule in human decidual cells by Ito (1994)10.4049/jimmunol.151.5.2380
/ J. Immunol. / CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells by Ellis (1993)10.1016/S0092-8674(00)81031-4
/ Cell / Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice by Amakawa (1996)10.4049/jimmunol.158.5.2090
/ J. Immunol. / Reciprocal regulation of CD30 expression on CD4+ T cells by IL-4 and IFN-gamma by Nakamura (1997)10.1002/eji.1830250742
/ Eur. J. Immunol. / Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed–Sternberg cells by Gruss (1995)10.1084/jem.180.6.2407
/ J. Exp. Med. / CD30 expression by CD8+ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+CD30+ T cell clones in human immunodeficiency virus infection by Manetti (1994)10.1084/jem.182.6.1655
/ J. Exp. Med. / CD30-mediated signaling promotes the development of human T helper type 2-like T cells by Del Prete (1995)10.1159/000237532
/ Int. Arch. Allergy Immunol. / An update on human Th1 and Th2 cells by Romagnani (1997)10.1002/jlb.58.6.683
/ J. Leukoc. Biol. / Not only Th2 cells but also Th1 and Th0 cells express CD30 after activation by Bengtsson (1995)10.4049/jimmunol.156.4.1387
/ J. Immunol. / CD30 expression does not discriminate between human Th1- and Th2-type T cells by Hamann (1996)10.1093/intimm/9.5.713
/ Int. Immunol. / Human CD30+ cells are induced by Mycobacterium tuberculosis and present in tuberculosis lesions by Munk (1997)10.4049/jimmunol.153.7.2861
/ J. Immunol. / CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity by Alzona (1994)10.4049/jimmunol.154.1.9
/ J. Immunol. / IL-12 activates IFN-gamma production through the preferential activation of CD30+ T cells by Alzona (1995)10.1002/eji.1830260209
/ Eur. J. Immunol. / CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: Evidence for a T helper 2-mediated condition by Chilosi (1996){'key': '10.1006/clim.1998.4636_RF47', 'first-page': '339', 'article-title': 'Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity', 'volume': '13', 'author': 'Caligaris-Cappio', 'year': '1995', 'journal-title': 'Clin. Exp. Rheumatol.'}
/ Clin. Exp. Rheumatol. / Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity by Caligaris-Cappio (1995)10.1111/j.1365-2249.1995.tb03851.x
/ Clin. Exp. Immunol. / High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints by Gerli (1995)10.1016/S0002-9343(97)00049-1
/ Am. J. Med. / High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis by Wang (1997){'key': '10.1006/clim.1998.4636_RF50', 'first-page': '1751', 'article-title': 'Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis', 'volume': '151', 'author': 'Mavalia', 'year': '1997', 'journal-title': 'Am. J. Pathol.'}
/ Am. J. Pathol. / Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis by Mavalia (1997)10.1046/j.1365-2249.1996.d01-823.x
/ Clin. Exp. Immunol. / Spontaneous CD30 mRNA expression in peripheral blood mononuclear cells from atopic patients with high IgE serum levels by Esnault (1996)10.1001/archderm.1996.03890340031006
/ Arch. Dermatol. / Circulating skin-homing T cells in atopic dermatitis by Piletta (1996)10.1128/JVI.72.4.3138-3145.1998
/ J. Virol. / Herpesvirus saimiri transforms human T-cell clones to stable growth without inducing resistance to apoptosis by Kraft (1998)10.4049/jimmunol.159.2.1012
/ J. Immunol. / CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes by Woitas (1997)10.1046/j.1365-2249.1996.915607.x
/ Clin. Exp. Immunol. / Serum levels of soluble CD30 in chronic hepatitis B virus infection by Fattovich (1996)10.1046/j.1365-2249.1997.d01-1005.x
/ Clin. Exp. Immunol. / High serum level of soluble CD30 in acute primary HIV-1 infection by Pizzolo (1997){'key': '10.1006/clim.1998.4636_RF57', 'first-page': '43', 'article-title': 'Soluble CD30, tumour necrosis factor (TNF)-alpha, and TNF receptors in primary HIV-1 infection: Relationship with HIV-1, RNA, clinical outcome and early antiviral therapy', 'volume': '11', 'author': 'Rizzardi', 'year': '1997', 'journal-title': 'J. Biol. Regul. Homeost. Agents'}
/ J. Biol. Regul. Homeost. Agents / Soluble CD30, tumour necrosis factor (TNF)-alpha, and TNF receptors in primary HIV-1 infection: Relationship with HIV-1, RNA, clinical outcome and early antiviral therapy by Rizzardi (1997)10.1097/00002030-199611000-00001
/ Aids / Plasma levels of soluble CD30, tumour necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: Correlation with HIV-1 RNA and the clinical outcome by Rizzardi (1996)10.1016/1074-7613(95)90094-2
/ Immunity / Activation of HIV expression by CD30 triggering in CD4+ T cells from HIV-infected individuals by Maggi (1995)10.1073/pnas.94.4.1390
/ Proc. Natl. Acad. Sci. USA / CD30 induction of human immunodeficiency virus gene transcription is mediated by TRAF2 by Tsitsikov (1997){'key': '10.1006/clim.1998.4636_RF61', 'first-page': '463', 'article-title': 'CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule', 'volume': '146', 'author': 'Latza', 'year': '1995', 'journal-title': 'Am. J. Pathol.'}
/ Am. J. Pathol. / CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule by Latza (1995)10.1016/0046-8177(94)90125-2
/ Hum. Pathol. / Ber-H2 expression in testicular germ cell tumors by Ferreiro (1994)10.1016/S0046-8177(96)90310-X
/ Hum. Pathol. / CD30 expression in seminoma by Hittmair (1996)10.1111/j.1699-0463.1998.tb01332.x
/ Apmis / CD30 and its ligand: possible role in regulation of teratoma stem cells by Pera (1998){'key': '10.1006/clim.1998.4636_RF65', 'first-page': '291', 'article-title': "The distinction of Hodgkin's disease from anaplastic large cell lymphoma", 'volume': '9', 'author': 'Frizzera', 'year': '1992', 'journal-title': 'Semin. Diagn. Pathol.'}
/ Semin. Diagn. Pathol. / The distinction of Hodgkin's disease from anaplastic large cell lymphoma by Frizzera (1992)10.1111/j.1365-2559.1989.tb02198.x
/ Histopathology / Lymphoma phenotyping in formalin-fixed and paraffin wax-embedded tissues: II by Norton (1989)10.1097/00000478-199405000-00014
/ Am. J. Surg. Pathol. / Nodular lymphocyte predominance Hodgkin's disease by Mason (1994)10.1073/pnas.91.23.10962
/ Proc. Natl. Acad. Sci. USA / Hodgkin disease: Hodgkin and Reed–Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development by Kuppers (1994)10.1073/pnas.94.17.9337
/ Proc. Natl. Acad. Sci. USA / Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells by Braeuninger (1997)10.1056/NEJM199708143370704
/ N. Engl. J. Med. / Clonality in nodular lymphocyte-predominant Hodgkin's disease [see comments by Ohno (1997)10.1056/NEJM199708143370703
/ N. Engl. J. Med. / Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells [see Comments] by Marafioti (1997)10.1182/blood.V87.2.465.bloodjournal872465
/ Blood / Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease by Falini (1996)10.1182/blood.V86.1.45.bloodjournal86145
/ Blood / BCL-6 protein is expressed in germinal-center B cells by Cattoretti (1995)10.1182/blood.V86.1.28.bloodjournal86128
/ Blood / BCL-6 gene product, a 92- to 98-kD nuclear phosphoprotein, is highly expressed in germinal center B cells and their neoplastic counterparts by Onizuka (1995)10.1111/j.1365-2141.1990.tb02664.x
/ Br. J. Haematol. / Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: Relationship with disease activity and clinical stage by Pizzolo (1990)10.1182/blood.V77.9.1983.1983
/ Blood / Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease by Gause (1991)10.1182/blood.V91.8.3011.3011_3011_3016
/ Blood / Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome by Nadali (1998)10.1200/JCO.1995.13.6.1355
/ J. Clin. Oncol. / Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma by Nadali (1995)10.1111/j.1365-2141.1992.tb08208.x
/ Br. J. Haematol. / Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: In vitro evaluation by Tazzari (1992)10.1182/blood.V85.8.2139.bloodjournal8582139
/ Blood / Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma by Pasqualucci (1995)10.4049/jimmunol.155.5.2369
/ J. Immunol. / Regulation of human B cell function by recombinant CD40 ligand and other TNF-related ligands by Jumper (1995)10.1056/NEJM198902233200806
/ N. Engl. J. Med. / Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease by Weiss (1989)10.1073/pnas.88.11.4766
/ Proc. Natl. Acad. Sci. USA / Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells by Herbst (1991)10.1128/jvi.65.1.415-423.1991
/ J. Virol. / Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene by Zimber-Strobl (1991)10.1136/jcp.47.1.33
/ J. Clin. Pathol. / Relation of CD30 expression to survival and morphology in large B cell lymphomas by Noorduyn (1994)10.1002/1097-0142(19930315)71:6<2097::AID-CNCR2820710626>3.0.CO;2-7
/ Cancer / Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis by Beljaards (1993)10.1084/jem.183.2.669
/ J. Exp. Med. / T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors by Lee (1996)10.1182/blood.V87.6.2443.bloodjournal8762443
/ Blood / Activation of Hodgkin cells via the CD30 receptor induces autocrine secretion of interleukin-6 engaging the NF-kappabeta transcription factor by Gruss (1996)10.1615/CritRevOncog.v5.i5.30
/ Crit. Rev. Oncog. / Hodgkin's disease: A cytokine-producing tumor—A review by Gruss (1994)10.1182/blood.V84.7.2305.2305
/ Blood / Expression and function of CD40 on Hodgkin and Reed–Sternberg cells and the possible relevance for Hodgkin's disease by Gruss (1994)10.1016/S1074-7613(00)80390-8
/ Immunity / TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival by Lee (1997)10.1016/S1074-7613(00)80391-X
/ Immunity / Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice by Yeh (1997)10.1016/1074-7613(95)90113-2
/ Immunity / A role for the orphan steroid receptor Nur77 in apoptosis accompanying antigen-induced negative selection by Calnan (1995)10.1084/jem.185.7.1275
/ J. Exp. Med. / TRAF-interacting protein (TRIP): A novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation by Lee (1997)10.1101/gad.11.21.2810
/ Genes Dev. / CD30-dependent degradation of TRAF2: Implications for negative regulation of TRAF signaling and the control of cell survival by Duckett (1997)10.1016/S1074-7613(00)80607-X
/ Immunity / CD30 is a CD40-inducible molecule that negatively regulates CD40-mediated immunoglobulin class switching in non-antigen-selected human B cells by Cerutti (1998)10.1002/eji.1830250805
/ Eur. J. Immunol. / Regulation of murine B cell growth and differentiation by CD30 ligand by Shanebeck (1995)10.4049/jimmunol.157.8.3635
/ J. Immunol. / Reverse signaling via CD30 ligand by Wiley (1996)10.1016/S0167-5699(97)84661-0
/ Immunol. Today / Hodgkin's disease: a tumor with disturbed immunological pathways by Gruss (1997)10.1182/blood.V88.9.3299.bloodjournal8893299
/ Blood / Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line by Pinto (1996){'key': '10.1006/clim.1998.4636_RF101', 'first-page': '469', 'article-title': "CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues", 'volume': '149', 'author': 'Gruss', 'year': '1996', 'journal-title': 'Am. J. Pathol.'}
/ Am. J. Pathol. / CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues by Gruss (1996)
Dates
Type | When |
---|---|
Created | 22 years, 10 months ago (Oct. 6, 2002, 3:13 p.m.) |
Deposited | 2 years, 5 months ago (April 4, 2023, 12:22 p.m.) |
Indexed | 4 months, 1 week ago (April 24, 2025, 1:47 a.m.) |
Issued | 26 years, 7 months ago (Feb. 1, 1999) |
Published | 26 years, 7 months ago (Feb. 1, 1999) |
Published Print | 26 years, 7 months ago (Feb. 1, 1999) |
@article{Chiarle_1999, title={CD30 in Normal and Neoplastic Cells}, volume={90}, ISSN={1521-6616}, url={http://dx.doi.org/10.1006/clim.1998.4636}, DOI={10.1006/clim.1998.4636}, number={2}, journal={Clinical Immunology}, publisher={Elsevier BV}, author={Chiarle, Roberto and Podda, Antonello and Prolla, Gabriel and Gong, Jerry and Thorbecke, G.Jeanette and Inghirami, Giorgio}, year={1999}, month=feb, pages={157–164} }